替格瑞洛与氯吡格雷在ACS行PCI患者中的净不良临床事件关联
该回顾性队列研究基于美国两个电子健康记录数据库和韩国一个全国数据库,纳入2011年11月至2019年3月因ACS行PCI并接受替格瑞洛或氯吡格雷治疗的患者,经倾向评分匹配后分析12个月净不良临床事件(NACE)。结果显示替格瑞洛与氯吡格雷的NACE风险无显著差异,但替格瑞洛组出血事件和呼吸困难风险显著更高。
核心结论
- 在常规临床实践中,ACS行PCI患者使用替格瑞洛与氯吡格雷相比,12个月NACE风险无显著差异。
- 替格瑞洛组出血事件和呼吸困难风险显著高于氯吡格雷组。
- 由于不能排除未测量混杂因素,尚需进一步研究确定替格瑞洛是否优于氯吡格雷。
研究设计与样本
- 回顾性队列研究,使用美国2个电子健康记录数据库和韩国1个全国数据库,时间2011年11月至2019年3月。
- 纳入ACS行PCI并接受替格瑞洛或氯吡格雷治疗的患者,经大规模倾向评分算法匹配。
- 95.5%患者同时服用阿司匹林。
- 数据库水平风险比通过随机效应荟萃分析汇总。
临床怎么用
- 在ACS行PCI患者中,选择替格瑞洛或氯吡格雷时需权衡缺血与出血风险。
- 替格瑞洛组出血和呼吸困难风险较高,临床应加强监测。
- 常规实践中替格瑞洛与氯吡格雷的NACE风险无显著差异,决策应个体化。
局限性
- 不能排除未测量混杂因素的影响。
- 研究为回顾性队列设计,可能存在残余混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Current guidelines recommend ticagrelor as the preferred P2Y12 platelet inhibitor for patients with acute coronary syndrome (ACS), primarily based on a single large randomized clinical trial. The benefits and risks associated with ticagrelor vs clopidogrel in routine practice merits attention. OBJECTIVE: To determine the association of ticagrelor vs clopidogrel with ischemic and hemorrhagic events in patients undergoing percutaneous coronary intervention (PCI) for ACS in clinical practice. DESIGN, SETTING, AND PARTICIPANTS: A retrospective cohort study of patients with ACS who underwent PCI and received ticagrelor or clopidogrel was conducted using 2 United States electronic health record-based databases and 1 nationwide South Korean database from November 2011 to March 2019. Patients were matched using a large-scale propensity score algorithm, and the date of final follow-up was March 2019. EXPOSURES: Ticagrelor vs clopidogrel. MAIN OUTCOMES AND MEASURES: The primary end point was net adverse clinical events (NACE) at 12 months, composed of ischemic events (recurrent myocardial infarction, revascularization, or ischemic stroke) and hemorrhagic events (hemorrhagic stroke or gastrointestinal bleeding). Secondary outcomes included NACE or mortality, all-cause mortality, ischemic events, hemorrhagic events, individual components of the primary outcome, and dyspnea at 12 months. The database-level hazard ratios (HRs) were pooled to calculate summary HRs by random-effects meta-analysis. RESULTS: After propensity score matching among 31 290 propensity-matched pairs (median age group, 60-64 years; 29.3% women), 95.5% of patients took aspirin together with ticagrelor or clopidogrel. The 1-year risk of NACE was not significantly different between ticagrelor and clopidogrel (15.1% [3484/23 116 person-years] vs 14.6% [3290/22 587 person-years]; summary HR, 1.05 [95% CI, 1.00-1.10]; P = .06). There was also no significant difference in the risk of all-cause mortality (2.0% for ticagrelor vs 2.1% for clopidogrel; summary HR, 0.97 [95% CI, 0.81-1.16]; P = .74) or ischemic events (13.5% for ticagrelor vs 13.4% for clopidogrel; summary HR, 1.03 [95% CI, 0.98-1.08]; P = .32). The risks of hemorrhagic events (2.1% for ticagrelor vs 1.6% for clopidogrel; summary HR, 1.35 [95% CI, 1.13-1.61]; P = .001) and dyspnea (27.3% for ticagrelor vs 22.6% for clopidogrel; summary HR, 1.21 [95% CI, 1.17-1.26]; P < .001) were significantly higher in the ticagrelor group. CONCLUSIONS AND RELEVANCE: Among patients with ACS who underwent PCI in routine clinical practice, ticagrelor, compared with clopidogrel, was not associated with significant difference in the risk of NACE at 12 months. Because the possibility of unmeasured confounders cannot be excluded, further research is needed to determine whether ticagrelor is more effective than clopidogrel in this setting.
引用
- You SC, Rho Y, Bikdeli B, et al. Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. JAMA. 2020. PMID: 33107944. doi:10.1001/jama.2020.16167
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。